He heads the DKFZ research program Translational Cancer Research, he is Deputy Chairman of the DKFZ Scientific Council, spokesperson of the Helmholtz initiative on personalized medicine iMed, spokesperson of the Comprehensive Cancer Center Network of German Cancer Aid, and member of the steering committee for various projects financed by the EU, DFG, BMBF, DKH and the German ICGC Consortium.
Christoph von Kalle coordinates the NCT's strategic orientation with the primary objective to use state-of-the-art scientific knowledge in translational and clinical research at DKFZ and Heidelberg University Hospital for targeted diagnostics, therapy and cancer prevention. Scientists and physicians from the Translational Oncology unit support patient care and the development of clinical studies at the NCT, and head internationally renowned research groups for stem cell research, molecular gene therapy, molecular and cellular oncology, lymphoma research, applied functional genomics and virotherapy. In the field of precision oncology, the Translational Oncology department coordinates the NCT Personalized Oncology Program NCT POP. The main focus is always the development of individualized cancer therapies for every single patient at the NCT.